Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News Beyondspring Inc BYSI

Healthcare Biotechnology
BeyondSpring Inc. is a clinical-stage global biopharmaceutical company. The Company is focused on developing innovative therapies to improve clinical outcomes for patients with high unmet medical needs. The Company operates through two segments: the Plinabulin pipeline and Targeted Protein Degradation (TPD) platform. Plinabulin is being developed as a pipeline in a drug in various cancer... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (NDAQ:BYSI)

BeyondSpring Presents Updated Efficacy Results from a Phase 2 IIT Study of Triple IO Combo of Pembrolizumab plus Plinabulin/Docetaxel in Metastatic NSCLC after Progressing on Prior Immune Checkpoint Inhibitors at the 39th SITC Annual Meeting

GlobeNewswire 11 days ago

BeyondSpring Presents Efficacy/Safety Results from a Phase 2 Study of Pembrolizumab plus Plinabulin/Docetaxel in Metastatic NSCLC after Progressing on First-Line Immune Checkpoint Inhibitors at ESMO Congress 2024

GlobeNewswire September 16, 2024

BeyondSpring Presents Final Data Analysis of DUBLIN-3 Phase 3 Study in 2L/3L EGFR Wild-type NSCLC at ESMO Congress 2024

GlobeNewswire September 16, 2024

BeyondSpring Delivers Oral Presentation at ISLAC 2024 World Conference on Lung Cancer of its Lead Anti-Cancer Asset Plinabulin Showcasing Positive Final Phase 3 Data in 2L/3L NSCLC EGFR Wild-Type with Concurrent Publication in the Lancet Respiratory Medicine

GlobeNewswire September 10, 2024

BeyondSpring Announces Oral Presentation at the 2024 World Conference on Lung Cancer and Two Poster Presentations During ESMO Congress 2024 Showcasing its Lead Anti-Cancer Asset, Plinabulin

GlobeNewswire September 3, 2024

SEED Therapeutics (SEED) Enters into Strategic Research Collaboration with Eisai Co., Ltd. to Discover and Develop Novel Molecular Glue Degraders for Neurodegeneration and Oncology Indications

GlobeNewswire August 6, 2024

BeyondSpring R&D Day Highlights New Plinabulin Development Strategy for Cancer and Updates for SEED Therapeutics

GlobeNewswire May 16, 2024

BeyondSpring To Host Virtual R&D Day to Discuss New Plinabulin Development Strategy for Cancer and Updates for SEED Therapeutics

GlobeNewswire May 3, 2024

BeyondSpring Provides Business Update and Reports Year End 2023 Financial Results

GlobeNewswire April 29, 2024
View More News ››

Opinion & Analysis (NDAQ:BYSI)

Biotech advances potential 'billion-dollar drug' with new trial launch in China

Streetwise Reports December 8, 2017
View More Opinion ››

Bullboard Posts (NDAQ:BYSI)

BeyondSpring Presents Updated Efficacy Results from a Phase

Just In: $BYSI BeyondSpring Presents Updated Efficacy Results from a Phase 2 IIT Study of Triple IO Combo of Pembrolizumab plus...
whytestocks - 10 days ago

RE:REAL DEAL

From last quarterly report:  "As of September 30, 2021, the Company had cash, cash equivalents, and short-term investments of ...
dmacd - March 14, 2022

RE:Compelling despite Headwinds

Well if it goes to $3/sh or cash valuation then it is time for me to double down. I did not think that chance would come. The market is...
dmacd - January 19, 2022

Compelling despite Headwinds

$90M cash vs $128M MC. Way too low for a company this advanced. FDA caused job losses in US with their approach. Would be nice to get...
dmacd - January 12, 2022

RE:REAL DEAL

Blockbuster is probable. Strongest terms with a Chinese entity I have seen in quite some time for an emerging player. $45M cash up front...
dmacd - August 26, 2021

REAL DEAL

disruptive lung cancer treatment on verge of FDA approval
Felix12345 - August 23, 2021
View more Bullboard ››

Western Metallica Resources Corp.

Western Metallica Resources Corp.

Western Metallica Resources Corp. is a Canada-based mineral exploration company with five mineral assets across Peru and ...
View More »